… At least one large-scale trial of a synthetic surfactant failed to … air spaces of patients with
ALI/ARDS has generated several … with ALI/ARDS (70) as well as in patients at risk of ALI/ARDS (…

… pro-inflammatory mediators in ALI/ARDS at the mRNA level 19 … pulmonary route for the
treatment of ALI/ARDS and we discuss … a great impact on ALI/ARDS since surfactant production is …

… Future developments will need to further refine this lung protective concept. … during the
ventilatory cycle. For example, a low V/Q relationship at end inspiration could become a shunt at …

… The 4 phases of ALI/ARDS follow a predictable pattern that … Given the important role that
surfactant and its loss at the … As we look toward the future of pharmacologic intervention there …

… which surfactant might accomplish this is through … future studies could examine if exogenous
surfactant therapy can duplicate the results observed with increased endogenous surfactant …

… lung surfactant is dysfunctional in ALI/ARDS ( 1–8 ). Given the unequivocal success of
exogenous surfactant administration … Future investigation should evaluate the effect of surfactant …

… surfactant inactivation in ALI/ARDS and addresses how its circumvention may lead to improved
surfactant treatment … better and less expensive surfactants will be available in the future. …

… treat ALI/ARDS and expects to use 3D models for future … -II cells, which can synthesize and
secrete alveolar surfactant, … immune cells through related signal pathways to participate in the …

… in ALI/ARDS and their relationship with the lung surfactant and the potential therapeutic
use of … of action should be considered for clinical evaluation during the therapy of ALI/ARDS. …

… Conversely, ALI/ARDS may contribute to morbidity and … formula and route of administration
of surfactant, with the aim … effective and new drugs in future trials. Promising agents for …